Positive topline data from phase Ib study of CBP-201 in moderate to severe atopic dermatitis Jan. 9, 2020
Novan reports topline efficacy data from phase III B-SIMPLE program of SB-206 for molluscum Jan. 3, 2020
One down, two left: Durect discontinues developing DUR-928 to treat psoriasis Jan. 2, 2020 By Lee Landenberger Earlier this week, Durect Corp.’s DUR-928 was being tested in three different indications. But by week’s end, it’s now down to two. Read More
Sol-Gel shares get an end-of-year boost from two pivotal phase III studies Dec. 31, 2019 By Lee Landenberger Positive top-line data from two pivotal phase III studies of acne vulgaris treatment Twyneo from Sol-Gel Technologies Ltd. is doing the stock end-of the-year favors as shares closed up 19% at $17.50 on Tuesday. Read More
Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study Dec. 31, 2019
Topline data presented from E.U. phase III study of Wynzora Cream for psoriasis vulgaris Dec. 20, 2019
RSS
